ResMed (MEX:RMD) Research & Development: MXN6,567 Mil (TTM As of Mar. 2026)


MEX:RMD ResMed Inc MEX:RMD
99 GF Score
Price MXN3,716.10
GF Value MXN5,298.64
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed Research & Development?

ResMed MEX:RMD 99 Research & Development is MXN6,567 Mil as of Mar. 2026. GuruFocus rates MEX:RMD with a GF Score™ of 99/100 and a GF Value™ of MXN5,298.64 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. ResMed's Research & Development for the three months ended in Mar. 2026 was MXN1,700 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was MXN6,567 Mil.

ResMed  (MEX:RMD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

ResMed Research & Development Related Terms

ResMed Research & Development Historical Data

* Premium members only.

The historical data trend for ResMed's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Research & Development Chart

ResMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,484.50 5,101.42 4,931.31 5,633.89 6,237.81

ResMed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,717.34 1,627.67 1,601.87 1,637.96 1,699.89
MEX:RMD
99GF Score
ResMed Inc MEX:RMD
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN6,567 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN6,567 Mil mean?
ResMed (MEX:RMD) has a Research & Development of MXN6,567 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on ResMed and its competitors.
Is ResMed's Research & Development too high?
ResMed's current Research & Development is MXN6,567 Mil. Overall, ResMed has a GF Score™ of 99/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Research & Development compare to MDLN and WST?
ResMed's Research & Development of MXN6,567 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on ResMed and its competitors. ResMed's current Research & Development is MXN6,567 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN5,298.64, compared to a current price of MXN3,716.10 — trading 29.9% below its estimated fair value. The current Research & Development is MXN6,567 Mil. ResMed's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For ResMed (MEX:RMD), the current Research & Development is MXN6,567 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (MEX:RMD) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of MXN3,716.10 is trading 29.9% below its estimated GF Value™ of MXN5,298.64. GuruFocus considers ResMed to be Significantly Undervalued.

Key valuation signals for MEX:RMD:

  • Research & Development: MXN6,567 Mil
  • GF Value™: MXN5,298.64 vs. price of MXN3,716.10 (29.9% below fair value)
  • GF Score™: 99/100 with 1 warning sign

No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
99GF Score

Get the complete analysis for MEX:RMD

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,716.10
Price
MXN5,298.64
GF Value